sábado, 21 de marzo de 2026

Clinical Perspectives on the Use of PI3K/AKT Pathway Inhibitors in the Management of HR+/HER2− Metastatic Breast Cancer Authors: Peter Schmid, MD, PhD, FRCP; Kevin Kalinsky, MD, MS, FASCO; Frédérique Penault-Llorca, MD, PhD

https://www.medscape.org/viewarticle/clinical-perspectives-use-pi3k-akt-pathway-inhibitors-2026a100087h?page=1&uac=148436CN&sso=true&src=wnl_tpal_260320_mscpedu&impID=8203361

No hay comentarios:

Publicar un comentario